- Published on
Emergency and Acute Medicine – Cardiomyopathy
Foundational Overview
Cardiomyopathies are disorders of the myocardium associated with structural and functional cardiac impairment. Major forms include dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and unclassified variants. Specific cardiomyopathies occur secondary to systemic diseases or identifiable conditions. Dilated cardiomyopathy accounts for approximately 25% of all heart failure cases and is the most common subtype encountered in emergency care.
Causative Mechanisms
Dilated cardiomyopathy may be idiopathic, viral, genetic, toxic, immune mediated, or familial. Hypertrophic cardiomyopathy is typically an autosomal dominant inherited disorder. Restrictive cardiomyopathy may be idiopathic or related to infiltrative diseases such as amyloidosis. Arrhythmogenic right ventricular cardiomyopathy is usually familial with either dominant or recessive inheritance. Secondary cardiomyopathies include infectious causes such as viral myocarditis, Lyme disease, Chagas disease, and HIV; toxic causes such as alcohol, chemotherapeutic agents, and peripartum states; metabolic causes including hyperthyroidism, pheochromocytoma, and stress-induced (Takotsubo) cardiomyopathy; and systemic diseases such as lupus, scleroderma, neuromuscular disorders, and amyloidosis.
Pediatric-Specific Etiologies
In children, cardiomyopathy may be idiopathic or genetic, including inborn errors of metabolism, neuromuscular disease, malformation syndromes, and familial isolated cardiomyopathies. Acquired causes include nutritional deficiencies, electrolyte and endocrine disturbances, toxins, collagen vascular disease, immunologic disorders, malignancy, morbid obesity, myocarditis, pulmonary disease, Kawasaki disease, infections, radiation, congenital heart disease, and perinatal asphyxia.
Clinical Manifestations
History may reveal antecedent viral illness, chemotherapy exposure, HIV, Lyme disease, pregnancy, substance use, or systemic conditions such as hemochromatosis or sarcoidosis. Family history of sudden cardiac death is a critical clue. Symptoms include exertional dyspnea, dizziness, palpitations, near-syncope or syncope, ventricular arrhythmias, and congestive heart failure. Pediatric presentations may include irritability, hepatomegaly, generalized weakness, hypoglycemia, metabolic acidosis, hyperammonemia, cyanosis, encephalopathy, and dysmorphic features. Pregnancy-related cardiomyopathy should be considered separately.
Initial Assessment Priorities
Evaluation focuses on vital signs, cardiopulmonary examination, evidence of volume overload, abdominal organomegaly, peripheral edema, and signs of systemic disease such as rash or goiter. Rapid identification of decompensated heart failure, malignant arrhythmias, or shock is essential.
Diagnostic Evaluation
Laboratory studies include CBC, metabolic panel, liver and thyroid function tests, cardiac biomarkers, and BNP (levels >100 pg/mL support heart failure). Serologic testing is rarely helpful in the emergency setting. Chest radiography may demonstrate cardiomegaly, pulmonary congestion, and pleural effusions in dilated cardiomyopathy, whereas restrictive cardiomyopathy often shows a normal cardiac silhouette with pulmonary congestion. Emergency bedside transthoracic echocardiography may reveal depressed LV ejection fraction and exclude pericardial tamponade. Formal echocardiography is the diagnostic study of choice to characterize chamber size, wall thickness, systolic and diastolic function, and valvular disease. CT and cardiac MRI help differentiate restrictive cardiomyopathy from constrictive pericarditis and provide detailed assessment of myocardial anatomy, fibrosis, infiltration, iron overload, and viability.
Electrocardiographic Patterns
Hypertrophic cardiomyopathy commonly shows LV hypertrophy and deep Q waves in inferolateral leads, particularly in adolescents. Dilated, toxic, Lyme, and Chagas cardiomyopathies may present with atrial fibrillation, heart block, conduction delays, or pseudoinfarct patterns. Stress-induced (Takotsubo) cardiomyopathy may mimic STEMI and often necessitates cardiac catheterization to exclude ischemia.
Important Differentials
Other causes of dyspnea include COPD, asthma, anemia, interstitial lung disease, pulmonary embolism, pericardial tamponade, valvular disease, ischemic heart disease, hypothyroidism, and constrictive pericarditis. Syncope differentials include hypovolemia, hypoglycemia, heat illness, arrhythmia, and cardiac ischemia.
Prehospital Considerations
Patients require monitoring, supplemental oxygen, and cautious use of nitrates, particularly in suspected hypertrophic cardiomyopathy. Decompensated heart failure may benefit from nitrates and noninvasive positive-pressure ventilation.
Emergency Stabilization
Management prioritizes airway, breathing, and circulation with oxygen supplementation and noninvasive ventilation when indicated. Intubation is reserved for respiratory failure or severe encephalopathy.
Definitive Emergency Management
Treatment focuses on standard heart failure and arrhythmia protocols. Anticoagulation is indicated in dilated cardiomyopathy with atrial fibrillation or embolic risk. Atrial fibrillation and ventricular dysrhythmias are managed per ACLS principles. In hypertrophic cardiomyopathy, negative inotropes such as beta-blockers or disopyramide may reduce outflow obstruction. Special pediatric considerations include keeping patients NPO until inborn metabolic errors are excluded, administering dextrose-containing fluids cautiously, and avoiding lactate-containing solutions. Carnitine, antioxidants, and vitamin cofactors may be required in metabolic disorders.
Common Emergency Medications
Therapies may include amiodarone, beta-blockers, calcium channel blockers, diuretics, nitrates, anticoagulation, milrinone, nesiritide, and disease-specific agents such as carnitine, with careful age- and comorbidity-adjusted dosing.
Disposition Planning
Admission is required for new or suspected cardiomyopathy, syncope with concern for arrhythmia or hypertrophic cardiomyopathy, family history of sudden death, cardiogenic shock, or significant decompensation. Discharge may be considered for known cardiomyopathy with mild heart failure responding to treatment, typically after cardiology consultation.
Referral and Follow-Up
Patients with reduced ejection fraction (<35%) may require referral for implantable cardioverter-defibrillators, biventricular pacing, ventricular assist devices, or transplant evaluation. ongoing cardiology follow-up and consideration of genetic testing are essential.< />pan>
Clinical Insights
Bedside echocardiography is a powerful emergency tool in patients with syncope or exertional symptoms. A thorough family history is critical, as inherited cardiomyopathies are a major cause of sudden cardiac death in young patients.
Foundational Overview
Cardiomyopathies are disorders of the myocardium associated with structural and functional cardiac impairment. Major forms include dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and unclassified variants. Specific cardiomyopathies occur secondary to systemic diseases or identifiable conditions. Dilated cardiomyopathy accounts for approximately 25% of all heart failure cases and is the most common subtype encountered in emergency care.
Causative Mechanisms
Dilated cardiomyopathy may be idiopathic, viral, genetic, toxic, immune mediated, or familial. Hypertrophic cardiomyopathy is typically an autosomal dominant inherited disorder. Restrictive cardiomyopathy may be idiopathic or related to infiltrative diseases such as amyloidosis. Arrhythmogenic right ventricular cardiomyopathy is usually familial with either dominant or recessive inheritance. Secondary cardiomyopathies include infectious causes such as viral myocarditis, Lyme disease, Chagas disease, and HIV; toxic causes such as alcohol, chemotherapeutic agents, and peripartum states; metabolic causes including hyperthyroidism, pheochromocytoma, and stress-induced (Takotsubo) cardiomyopathy; and systemic diseases such as lupus, scleroderma, neuromuscular disorders, and amyloidosis.
Pediatric-Specific Etiologies
In children, cardiomyopathy may be idiopathic or genetic, including inborn errors of metabolism, neuromuscular disease, malformation syndromes, and familial isolated cardiomyopathies. Acquired causes include nutritional deficiencies, electrolyte and endocrine disturbances, toxins, collagen vascular disease, immunologic disorders, malignancy, morbid obesity, myocarditis, pulmonary disease, Kawasaki disease, infections, radiation, congenital heart disease, and perinatal asphyxia.
Clinical Manifestations
History may reveal antecedent viral illness, chemotherapy exposure, HIV, Lyme disease, pregnancy, substance use, or systemic conditions such as hemochromatosis or sarcoidosis. Family history of sudden cardiac death is a critical clue. Symptoms include exertional dyspnea, dizziness, palpitations, near-syncope or syncope, ventricular arrhythmias, and congestive heart failure. Pediatric presentations may include irritability, hepatomegaly, generalized weakness, hypoglycemia, metabolic acidosis, hyperammonemia, cyanosis, encephalopathy, and dysmorphic features. Pregnancy-related cardiomyopathy should be considered separately.
Initial Assessment Priorities
Evaluation focuses on vital signs, cardiopulmonary examination, evidence of volume overload, abdominal organomegaly, peripheral edema, and signs of systemic disease such as rash or goiter. Rapid identification of decompensated heart failure, malignant arrhythmias, or shock is essential.
Diagnostic Evaluation
Laboratory studies include CBC, metabolic panel, liver and thyroid function tests, cardiac biomarkers, and BNP (levels >100 pg/mL support heart failure). Serologic testing is rarely helpful in the emergency setting. Chest radiography may demonstrate cardiomegaly, pulmonary congestion, and pleural effusions in dilated cardiomyopathy, whereas restrictive cardiomyopathy often shows a normal cardiac silhouette with pulmonary congestion. Emergency bedside transthoracic echocardiography may reveal depressed LV ejection fraction and exclude pericardial tamponade. Formal echocardiography is the diagnostic study of choice to characterize chamber size, wall thickness, systolic and diastolic function, and valvular disease. CT and cardiac MRI help differentiate restrictive cardiomyopathy from constrictive pericarditis and provide detailed assessment of myocardial anatomy, fibrosis, infiltration, iron overload, and viability.
Electrocardiographic Patterns
Hypertrophic cardiomyopathy commonly shows LV hypertrophy and deep Q waves in inferolateral leads, particularly in adolescents. Dilated, toxic, Lyme, and Chagas cardiomyopathies may present with atrial fibrillation, heart block, conduction delays, or pseudoinfarct patterns. Stress-induced (Takotsubo) cardiomyopathy may mimic STEMI and often necessitates cardiac catheterization to exclude ischemia.
Important Differentials
Other causes of dyspnea include COPD, asthma, anemia, interstitial lung disease, pulmonary embolism, pericardial tamponade, valvular disease, ischemic heart disease, hypothyroidism, and constrictive pericarditis. Syncope differentials include hypovolemia, hypoglycemia, heat illness, arrhythmia, and cardiac ischemia.
Prehospital Considerations
Patients require monitoring, supplemental oxygen, and cautious use of nitrates, particularly in suspected hypertrophic cardiomyopathy. Decompensated heart failure may benefit from nitrates and noninvasive positive-pressure ventilation.
Emergency Stabilization
Management prioritizes airway, breathing, and circulation with oxygen supplementation and noninvasive ventilation when indicated. Intubation is reserved for respiratory failure or severe encephalopathy.
Definitive Emergency Management
Treatment focuses on standard heart failure and arrhythmia protocols. Anticoagulation is indicated in dilated cardiomyopathy with atrial fibrillation or embolic risk. Atrial fibrillation and ventricular dysrhythmias are managed per ACLS principles. In hypertrophic cardiomyopathy, negative inotropes such as beta-blockers or disopyramide may reduce outflow obstruction. Special pediatric considerations include keeping patients NPO until inborn metabolic errors are excluded, administering dextrose-containing fluids cautiously, and avoiding lactate-containing solutions. Carnitine, antioxidants, and vitamin cofactors may be required in metabolic disorders.
Common Emergency Medications
Therapies may include amiodarone, beta-blockers, calcium channel blockers, diuretics, nitrates, anticoagulation, milrinone, nesiritide, and disease-specific agents such as carnitine, with careful age- and comorbidity-adjusted dosing.
Disposition Planning
Admission is required for new or suspected cardiomyopathy, syncope with concern for arrhythmia or hypertrophic cardiomyopathy, family history of sudden death, cardiogenic shock, or significant decompensation. Discharge may be considered for known cardiomyopathy with mild heart failure responding to treatment, typically after cardiology consultation.
Referral and Follow-Up
Patients with reduced ejection fraction (<35%) may require referral for implantable cardioverter-defibrillators, biventricular pacing, ventricular assist devices, or transplant evaluation. ongoing cardiology follow-up and consideration of genetic testing are essential.< />pan>
Clinical Insights
Bedside echocardiography is a powerful emergency tool in patients with syncope or exertional symptoms. A thorough family history is critical, as inherited cardiomyopathies are a major cause of sudden cardiac death in young patients.
0 Comments
